|Videos|January 6, 2018

Should Pregnant Women Get Flu Shots?

William Schaffner, MD explains why pregnant women should get vaccinated against flu.

William Schaffer, MD, medical director of the National Foundation for Infectious Diseases, explains why pregnant women should get vaccinated against flu.

Interview Transcript (modified slightly for readability):

“Women who are pregnant, if they get influenza, have rates of complications of influenza comparable to those of people aged 65 and older, and that’s not generally recognized. They’re more apt to get more seriously ill, and so, it’s very important to vaccinate pregnant women against influenza so they don’t get sick. But there’s a bonus. As they make antibodies, the protection against flu they’ll pass through the placenta into the newborn. And so, when that baby is born during the first six months of life, they will have passive protection from their mothers against influenza; so, it’s two for the price of one. And my obstetrician friends tell me that when they tell pregnant women that by getting vaccinated against flu they’ll protect their babies, they start rolling up their sleeves. It’s safe; that’s a very important message when you’re vaccinating a pregnant woman. It’s not only safe, it’s effective.”


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.